<DOC>
	<DOC>NCT01906489</DOC>
	<brief_summary>The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in patients with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.</brief_summary>
	<brief_title>20-Week Repeat Oral Dose Study of AKB-6548 in Subjects With Chronic Kidney Disease and Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<criteria>Key 18 to 82 years of age, inclusive Chronic Kidney Disease with a GFR category of G3aG5 and not yet on dialysis eGFR ≥ 10 and ≤ 65 mL/minute/1.73 m2 Anemia secondary to CKD with an ESA status and a Screening HGB as per protocol Iron replete with ferritin and TSAT levels as defined per protocol Key BMI &gt; 44.0 kg/m2 Red blood cell transfusion within 11 weeks prior to the Screening visit Androgen therapy within the previous 21 days prior to the Screening visit Intravenous iron within the past 4 weeks prior to the Screening visit AST or ALT &gt;1.8x ULN, alkaline phosphatase &gt;2x ULN, or total bilirubin &gt;1.5x ULN Screening ECG with QTc &gt; 500 msec Uncontrolled hypertension Class III or IV congestive heart failure Myocardial infarction, acute coronary syndrome, or stroke within 6 months prior to the Screening visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>82 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal insufficiency</keyword>
	<keyword>renal impairment</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>kidney</keyword>
	<keyword>oral anemia treatment</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>hypoxia-inducible factor</keyword>
	<keyword>HIF</keyword>
	<keyword>hypoxia-inducible factor prolyl-hydroxylase inhibitor</keyword>
	<keyword>HIF-PHI</keyword>
	<keyword>efficacy</keyword>
	<keyword>safety</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>